BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38201285)

  • 21. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
    Fernando TM; Piskol R; Bainer R; Sokol ES; Trabucco SE; Zhang Q; Trinh H; Maund S; Kschonsak M; Chaudhuri S; Modrusan Z; Januario T; Yauch RL
    Nat Commun; 2020 Nov; 11(1):5551. PubMed ID: 33144586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic algorithm for challenging blue cell sinonasal carcinoma.
    Laforga JB; Abdullah B
    Pathol Res Pract; 2023 Aug; 248():154683. PubMed ID: 37478521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.
    Kunimasa K; Nakamura H; Sakai K; Tamiya M; Kimura M; Inoue T; Nishino K; Kuhara H; Nakatsuka SI; Nishio K; Imamura F; Kumagai T
    Lung Cancer; 2019 Jun; 132():59-64. PubMed ID: 31097095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
    Fahiminiya S; Witkowski L; Nadaf J; Carrot-Zhang J; Goudie C; Hasselblatt M; Johann P; Kool M; Lee RS; Gayden T; Roberts CW; Biegel JA; Jabado N; Majewski J; Foulkes WD
    Oncotarget; 2016 Jan; 7(2):1732-40. PubMed ID: 26646792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients.
    Crombé A; Alberti N; Villard N; Pilleul F; Buy X; Le Loarer F; Kind M
    Eur Radiol; 2019 Sep; 29(9):4730-4741. PubMed ID: 30762113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.
    Lin DI; Allen JM; Hecht JL; Killian JK; Ngo NT; Edgerly C; Severson EA; Ali SM; Erlich RL; Ramkissoon SH; Vergilio JA; Ross JS; Elvin JA
    Mod Pathol; 2019 Nov; 32(11):1675-1687. PubMed ID: 31190001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sinonasal teratocarcinosarcoma: a clinical and pathological analysis.
    Yang S; Sun R; Liang J; Zhou Z; Zhou J; Rui J
    Int J Surg Pathol; 2013 Feb; 21(1):37-43. PubMed ID: 22923779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SMARCA4-deficient Sinonasal Carcinoma.
    Agaimy A; Weichert W
    Head Neck Pathol; 2017 Dec; 11(4):541-545. PubMed ID: 28176137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sinonasal teratocarcinosarcoma: a clinical, radiologic and pathologic study of 5 cases].
    Wang SY; Zhu L; Li SM; Lin L; Zheng SX; Wu YF; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Aug; 36(8):534-8. PubMed ID: 17980101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
    Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression.
    Masliah-Planchon J; Machet MC; Fréneaux P; Jourdain A; Mortemousque I; Raïs KA; Ballet S; Jouvet A; Figarella-Branger D; Delattre O; Bourdeaut F
    Pediatr Blood Cancer; 2016 Mar; 63(3):568-9. PubMed ID: 26469284
    [No Abstract]   [Full Text] [Related]  

  • 32. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. a pilot study.
    Kupryjańczyk J; Dansonka-Mieszkowska A; Moes-Sosnowska J; Plisiecka-Hałasa J; Szafron L; Podgórska A; Rzepecka IK; Konopka B; Budziłowska A; Rembiszewska A; Grajkowska W; Spiewankiewicz B
    Pol J Pathol; 2013 Dec; 64(4):238-46. PubMed ID: 24375037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
    Witkowski L; Carrot-Zhang J; Albrecht S; Fahiminiya S; Hamel N; Tomiak E; Grynspan D; Saloustros E; Nadaf J; Rivera B; Gilpin C; Castellsagué E; Silva-Smith R; Plourde F; Wu M; Saskin A; Arseneault M; Karabakhtsian RG; Reilly EA; Ueland FR; Margiolaki A; Pavlakis K; Castellino SM; Lamovec J; Mackay HJ; Roth LM; Ulbright TM; Bender TA; Georgoulias V; Longy M; Berchuck A; Tischkowitz M; Nagel I; Siebert R; Stewart CJ; Arseneau J; McCluggage WG; Clarke BA; Riazalhosseini Y; Hasselblatt M; Majewski J; Foulkes WD
    Nat Genet; 2014 May; 46(5):438-43. PubMed ID: 24658002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
    Xue Y; Meehan B; Fu Z; Wang XQD; Fiset PO; Rieker R; Levins C; Kong T; Zhu X; Morin G; Skerritt L; Herpel E; Venneti S; Martinez D; Judkins AR; Jung S; Camilleri-Broet S; Gonzalez AV; Guiot MC; Lockwood WW; Spicer JD; Agaimy A; Pastor WA; Dostie J; Rak J; Foulkes WD; Huang S
    Nat Commun; 2019 Feb; 10(1):557. PubMed ID: 30718506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perspectives and Issues in the Assessment of
    Armon S; Hofman P; Ilié M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.
    Perret R; Chalabreysse L; Watson S; Serre I; Garcia S; Forest F; Yvorel V; Pissaloux D; Thomas de Montpreville V; Masliah-Planchon J; Lantuejoul S; Brevet M; Blay JY; Coindre JM; Tirode F; Le Loarer F
    Am J Surg Pathol; 2019 Apr; 43(4):455-465. PubMed ID: 30451731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
    Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
    Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
    Wong NKY; Llaurado Fernandez M; Kommoss FKF; Praveen Kumar P; Kim H; Liu J; Zhang G; Coatham M; Lin YY; Haegert AM; Volik S; Le Bihan S; Collins CC; Fu Y; Postovit LM; von Deimling A; Wu R; Xue H; Wang Y; Köbel M; Carey MS; Lee CH
    Gynecol Oncol; 2023 Sep; 176():162-172. PubMed ID: 37556934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
    Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N
    Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.